DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/sj6jgd/cognitive) has announced the addition of the "Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AbbVie Inc.
- Amarantus Bioscience Holdings, Inc.
- Astellas Pharma Inc.
- Avineuro Pharmaceuticals, Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- FORUM Pharmaceuticals Inc.
- H. Lundbeck A/S
- Intra-Cellular Therapies, Inc.
- Iproteos S.L.
- Mnemosyne Pharmaceuticals, Inc.
- Neuralstem, Inc.
- Pfizer Inc.
- Saniona AB
- Siena Biotech S.p.A.
- SK Biopharmaceuticals Co., Ltd.
- Sunovion Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Upsher-Smith Laboratories, Inc.
- Vanda Pharmaceuticals Inc.
For more information visit http://www.researchandmarkets.com/research/sj6jgd/cognitive